<DOC>
	<DOCNO>NCT02302469</DOCNO>
	<brief_summary>The purpose study determine recommend dose lenalidomide subject relapse refractory Waldenstrom Macroglobulinemia .</brief_summary>
	<brief_title>Study Lenalidomide Relapse/Refractory Waldenstrom Macroglobulinemia</brief_title>
	<detailed_description>Waldenstrom Macroglobulinemia ( lymphoplasmacytic lymphoma , WM ) low-grade lymphoplasmacytic lymphoma characterize involvement bone marrow lymphoplasmacytic cell production immunoglobulin M monoclonal protein circulation . Waldenstrom Macroglobulinemia characterize anemia cytopenia due part clonal expansion bone marrow . In addition , infiltration liver , spleen , lymph node may occur 15-20 % patient leading enlargement organ . Finally , complication relate elevated serum monoclonal protein hyperviscosity may also occur . Waldenstrom macroglobulinemia incurable disease overall median survival 5-6 year development symptom . The median age diagnosis 63 year Options therapy patient relapsed/refractory Waldenstrom Macroglobulinemia include rituximab , alkylating agent , nucleoside analogues . Although novel agent , bortezomib thalidomide , still matter debate , several phase II study demonstrate novel agent , especially Bortezomib , active agent relapse refractory Waldenstrom Macroglobulinemia .The overall response rate single agent bortezomib study reach 80 % , major response observe 30-40 % patient . Therefore , need identify new therapeutic agent Waldenstrom Macroglobulinemia patient . In view success treatment patient Multiple Myeloma , immunomodulatory drug ( IMiDS ) test patient Waldenstrom Macroglobulinemia , although experience limit . Thalidomide nonmyelosuppressive , immunomodulatory , antiangiogenic may reasonable choice patient first-line therapy fail , disease relapse candidate alkylating nucleoside analogue therapy , patient pancytopenia . Twenty three Waldenstrom Macroglobulinemia patient evaluable phase II study thalidomide combination rituximab . Although overall major response rate 78 % 70 % , respectively ; tolerance concern , dose reduction thalidomide occur patient lead discontinuation 11 patient . Lenalidomide study Multiple Myeloma myelodysplastic syndrome find potent also lack neurotoxic prothrombotic adverse effect thalidomide . Based potent activity lenalidomide Multiple Myeloma lack neuropathy agent , base interesting result report thalidomide-rituximab phase II tril relapse/refractory Waldenstrom Macroglobulinemia , phase II study lenalidomide 25mg daily combination rituximab perform patient relapsed/refractory Waldenstrom Macroglobulinemia . Lenalidomide administer 3 week , follow one week pause intend duration 48 week . Patients receive one week therapy lenalidomide , rituximab ( 375mg/m2 ) administer weekly week 2-5 , 13-16 . Twelve patient evaluable overall major response rate 67 % 33 % , median time progression 15.6 month . Acute decrease hematocrit observe first 2 week lenalidomide therapy 13/16 ( 81 % ) patient median hematocrit decrease 4.4 % ( 1.7-7.2 % ) . Despite reduction initiation dose 5mg daily , anemia continue problematic without evidence hemolysis general myelosuppression . Therefore , mechanism pronounce anemia Waldenstrom Macroglobulinemia patient receive lenalidomide remains determine use agent among Waldenstrom Macroglobulinemia patient remain investigational .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>The important criterion patient eligibility include : 1 . Age &gt; =18 year 2 . Patients must receive prior therapy ( number therapy ) WM relapse refractory WM 3 . Eastern Cooperative Oncology Group performance score 0 2 4 . Hemoglobin &gt; = 10g/dL hematocrit &gt; = 30 % 5 . Absolute neutrophil count ( ANC ) &gt; 1000/mm3 platelet count &gt; 75,000/mm3 6 . Adequate organ function define serum glutamate pyruvate transaminase serum glutamate oxaloacetate transaminase &lt; 2 x International Unit/l Total bilirubin &gt; = 1.5 mg/dL Clearance creatinin &gt; 50 ml/mn 7 . Evaluable immunochemical abnormality include abnormal electrophoresis serum free light chain assay increase either kappa lambda light chain lev Key Exclusion criterion 1 . Any uncontrolled medical condition comorbidity might interfere subject 's participation 2 . Patients treat require corticosteroid &gt; 30mg/day 3 . Pregnant breast feeding female ( Lactating female must agree breast feed take lenalidomide ) 4 . Use experimental drug therapy within 28 day baseline 5 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug 6 . Known positive HIV infectious hepatitis , type A , B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Hematology</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
</DOC>